




STRUCTURAL  
CHEMISTRY

**Volume 75 (2019)**


**Supporting information for article:**

**Tautomeric polymorphism of the neuroactive inhibitor kynurenic acid**


**Dorota Pogoda, Jan Janczak, Sylwia Pawlak, Michael Zaworotko and Veneta Videnova-Adrabinska**




**Figure S1** DSC thermogram of form II.




**Figure S2** DSC thermogram of form III.




**Figure S3** DTA-TG curves of form III.




**Figure S4** The ATR-IR spectrum of form III.




**Figure S5** DSC thermogram of form IV.




**Figure S6** The ATR-IR spectrum of form IV.




**Figure S7** DSC thermogram of form V.




**Figure S8** The ATR-IR spectrum of form V.




**Figure S9** DSC thermogram of form VI.



**Figure S10** The ATR-IR spectrum of form VI.



**Figure S11** DSC thermogram of the commercial compound (form VII), heated up to the melting point.



**Figure S12** DSC thermogram of species VIII with second reheating. The commercial compound (species VII) is heated up to 200 °C to convert into high temperature phase (species VIII), then cooled and reheated up to the melting point.




Figure S13 TGA-DTA curves of form VII.





Figure S14 The ATR-IR spectrum of form VII.





**Figure S15** The micrographs of the transformed commercial compound (form VIII).